马达加斯加与布基纳法索血吸虫候选疫苗的成本效果分析
本研究在布基纳法索和马达加斯加利用马尔可夫模型评估血吸虫疫苗不同接种策略的成本效果,结果显示仅接种学龄儿童通常不具成本效果,纳入成人可显著改善成本效果;在马达加斯加RT3CU4-59策略每获得一个QALY需278美元,在布基纳法索该策略为优势策略。保护持续时间比疫苗效力对成本效果影响更大,且对全程免疫接种成本敏感。
要点
- 仅针对学龄儿童的接种策略在基础假设下通常不具成本效果
- 纳入成人的接种策略可显著改善两国的成本效果
- 马达加斯加RT3CU4-59策略ICER为278美元/QALY,布基纳法索该策略为优势策略
核心结论
- 血吸虫疫苗接种有潜力成为具成本效果的干预,但经济价值取决于疫苗特性、实施成本和目标人群。
- 纳入成人的接种策略可能带来更大健康与经济收益,尤其在高成人疾病负担或重症治疗费用高的地区。
研究设计与样本
- 研究在马达加斯加和布基纳法索构建马尔可夫模型,估算血吸虫病相关健康与经济结局。
- 增量成本效果比采用两国现场研究获得的疾病成本与健康相关生活质量数据估算。
- 评估多种接种策略及不同效力和保护持续时间的假设疫苗特征,并与不接种情景比较。
主要发现
- 仅针对学龄儿童的接种策略在基础假设下通常不具成本效果。
- 将接种扩展至成人可显著改善两国成本效果,因两国成人年龄别患病率仍高于学龄儿童。
- 马达加斯加RT3CU4-59策略的ICER为每获得一个质量调整生命年278美元。
- 布基纳法索同一策略为优势策略,与不接种相比产生额外QALY并降低总成本。
- 成本效果受保护持续时间影响大于疫苗效力,并对全程免疫接种成本敏感。
关键数值与推荐
- 马达加斯加RT3CU4-59策略:ICER为278美元/QALY。
- 布基纳法索RT3CU4-59策略:为优势策略,即产生额外QALY且降低总成本。
- 仅接种学龄儿童策略在基础假设下通常不具成本效果。
- 成本效果对保护持续时间较疫苗效力更敏感,也对全程免疫接种成本敏感。
临床怎么用
- 制定血吸虫疫苗政策时应优先考虑纳入成人接种策略,尤其在成人疾病负担高的地区。
- 疫苗研发与引进应重点关注保护持续时间和全程免疫接种成本。
- 仅针对学龄儿童的接种策略在基础假设下通常不具成本效果,不宜作为单一策略。
局限性
- 疫苗为假设性疫苗,其效力和保护持续时间为假设值而非实测数据。
- 模型依赖两国现场研究的疾病成本与健康相关生活质量数据,外推需谨慎。
- 研究仅涉及马达加斯加和布基纳法索,结论推广至其他流行区需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Schistosomiasis, a major neglected tropical disease, affects millions of people worldwide. Although mass drug administration with praziquantel remains the primary control strategy, vaccines are currently under development and may provide an additional tool for disease prevention. This study evaluated the cost-effectiveness of alternative schistosomiasis vaccination strategies in Madagascar and Burkina Faso to support future policy decisions. METHODS: A Markov model was developed to estimate the health and economic outcomes associated with schistosomiasis. Incremental cost-effectiveness ratios were estimated using the country-specific cost of illness and health-related quality-of-life data obtained from field-based studies in Madagascar and Burkina Faso. Multiple vaccination strategies and hypothetical vaccine profiles with varying efficacy and duration of protection were evaluated and compared with a no-vaccination scenario. RESULTS: Vaccination strategies targeting only school-aged children were generally not cost-effective under the base-case assumptions. Extending vaccination to adults substantially improved cost-effectiveness in both countries because age-specific prevalence remained higher among adults than among school-aged children in both countries, allowing vaccination strategies including adults to capture a larger share of the remaining disease burden. In Madagascar, the RT3CU4-59 strategy was associated with an ICER of US$278 per quality-adjusted life year gained. In Burkina Faso, the same strategy was dominant, generating additional quality-adjusted life years while reducing overall costs compared with no vaccination. Cost-effectiveness was influenced more strongly by the duration of protection than by vaccine efficacy and was also sensitive to the cost per fully immunized person. CONCLUSIONS: Schistosomiasis vaccination has the potential to be a cost-effective intervention, although its economic value depends strongly on vaccine characteristics, implementation costs, and the target population. Vaccination strategies including adults may provide greater health and economic benefits, particularly in settings with a high adult disease burden or high treatment costs for severe disease.
引用
- Hwang Y, Cakpo GE, Rakotozandrindrainy N, et al. Cost-effectiveness analysis of a hypothetical vaccine for schistosomiasis in Madagascar and Burkina Faso. Vaccine. 2026. PMID: 42447735. doi:10.1016/j.vaccine.2026.128936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。